Updated: Bayer cuts PhII orphan drug as it ups R&D spending, questions swirl around new CEO’s next moves

Amber Tong

Reynald Castañeda

Deputy Editor

Bayer has shuttered a Phase II program that the EMA had designated an orphan drug “for scientific reasons,” the German conglomerate disclosed in its half …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Updated: Bayer cuts PhII orphan drug as it ups R&D spending, questions swirl around new CEO’s next moves

Amber Tong

Reynald Castañeda

Deputy Editor

Sign up to read this article for free.

GSK plots regulatory filings for PBC itch after positive Phase 3 readout

Chinese drugmaker receives FDA warning letter after management hindered inspection

J&J, Protagonist reveal two Phase 3 wins for oral IL-23 drug that's expected to be a blockbuster

Biogen, UCB detail response rates in Phase 3 lupus trial after surprising success

NICE has 'done all we can' to negotiate for Enhertu coverage, reaffirms decision not to recommend

Are programs with compounded GLP-1s safe for your population?

Up­dat­ed: Bay­er cuts PhII or­phan drug as it ups R&D spend­ing, ques­tions swirl around new CEO’s next moves

Deputy Editor

Sign up to read this article for free.

Updated: Bayer cuts PhII orphan drug as it ups R&D spending, questions swirl around new CEO’s next moves